Menu

Rothwell Figg BiosimilarIP Blog

Skip navigation Menu
  • Regulatory
  • Legal
  • News
  • About RFEM
  • Search

Teva

Random entry RSS

You are here:

  1. Home
  2. Tag Archives: Teva
  • Posted in:

    • News

    Celltrion Files Three IPR Petitions Against Two More Rituximab Patents

    By C. Nichole Gifford April 4, 2017 Comments are off

    On March 31, 2017, Celltrion, Inc. (“Celltrion”) filed three new petition for inter partes review (“IPR”) of two additional patents...

    Read more

    Tagged with: Biogen, Celltrion, Genentech, IPR, Legal, News, PTAB, Rituxan®, Rituximab, Teva, USPTO

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion Targets Four More Herceptin® Patents in IPR Petitions

    By C. Nichole Gifford March 24, 2017 Comments are off

    On March 21, 2017, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent Nos....

    Read more

    Tagged with: Celltrion, Genentech, Herceptin®, IPR, Legal, News, PTAB, Roche, Teva, trastuzumab, USPTO

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion Files Three IPR Petitions on Rituximab Patents

    By C. Nichole Gifford March 17, 2017 Comments are off

    Celltrion, Inc. (“Celltrion”) filed three new petitions with the Patent Trial and Appeal Board (“PTAB”) on March 15, 2017 for inter...

    Read more

    Tagged with: Biogen, Celltrion, Genentech, IPR, Legal, News, PTAB, Rituxan®, Rituximab, Roche, Teva, USPTO

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion Files IPR Petition on Herceptin® Patent

    By C. Nichole Gifford February 22, 2017 Comments are off

    Celltrion, Inc. (“Celltrion”) filed a new petition with the Patent Trial and Appeal Board (“PTAB”) on February 21, 2017 for inter...

    Read more

    Tagged with: Celltrion, Genentech, Herceptin®, IPR, Legal, News, PTAB, Roche, Teva, trastuzumab, USPTO

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

Pages

  • Prev
  • 1
  • 2

Sign Up for Updates

Don’t worry. We don’t spam.

Practice Contacts

  • E. Anthony Figg

  • Joseph A. Hynds

  • Seth Cockrum

Featured Posts

  • U.S. – E.U. Mutual Recognition Agreement Will Reduce Costs

    August 1, 2019

  • House Democrats Seek to Remove Biologics Exclusivity Period From USMCA

    July 25, 2019

  • What Pharma Companies Must Do Globally to Benefit From Canada’s Patent Term Extension Framework

    July 22, 2019

Popular Tags

AbbVie adalimumab Amgen Avastin® bevacizumab Biocon Biogen Boehringer Ingelheim BPCIA Celltrion District Court EMA FDA Featured Federal Circuit Genentech Herceptin® Hospira Humira® Infliximab IPR Janssen Legal Litigation Mylan Neulasta® News Notice Requirement Patent Dance pegfilgrastim Pfizer PTAB Regeneron Regulatory Remicade® Rituxan® Rituximab Roche Samsung Bioepsis Sandoz Sanofi Supreme Court Teva trastuzumab USPTO
Opinions expressed in articles on www.BiosimilarsIP.com are solely those of the author only and do not necessarily reflect the views of Rothwell Figg Ernst & Manbeck, P.C., its clients, or any of its respective affiliates. These materials are for general information purposes only and should not be taken as legal advice per the full disclaimer below.

Contact Us

Email Us
202.783.6040
Our Location

Find Out More

  • About Us
  • Results
  • Careers
  • Practices
  • Publications
  • News & Events
  • Professionals

© 2019 Rothwell, Figg, Ernst & Manbeck, P.C. All Rights Reserved

  • Disclaimer
  • Privacy Policy
Back to Top